Laurien J Zeverijn

7PUBLICATIONS
65CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Microbial ecologyMolecular targetsInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 01, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn

|Sep 25, 2025
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.

Iris L Mimpen, Thomas W Battaglia, Miguel Parra-Martinez

|Oct 01, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn

|Jul 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia

|Jun 27, 2024
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.

Jade M van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts

|May 15, 2024
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.

Birgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen

Pageof 2

Frequent Collaborators

7 joint publications

Birgit S Geurts

7 joint publications

Emile E Voest

7 joint publications

Hans Gelderblom

6 joint publications

Henk Mw Verheul